Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–16 of 16 results
Advanced filters: Author: Friedrich Grimminger Clear advanced filters

  • Fibrocytes are monocyte-derived cells implicated in wound healing. Here, the authors utilise single cell RNA-seq, genetic ablation and multiplexed imaging to identify a fibrocyte population in lung cancer models, and use human lung cancer coculture systems to highlight their potential to modulate microenvironmental niche and sensitivity to endothelin blockade.

    • Andreas Weigert
    • Xiang Zheng
    • Rajkumar Savai
    ResearchOpen Access
    Nature Communications
    Volume: 13, P: 1-21

  • Chronic obstructive pulmonary disease is a severe inflammatory lung disease characterized by obstructed airflow from the lungs. Here, Seimetz et al. show that NADPH oxidase subunit 1 (NOXO1) is responsible for peroxynitrite formation from nitric oxide and superoxide and drives the development of smoke-induced emphysema and pulmonary hypertension.

    • Michael Seimetz
    • Natascha Sommer
    • Norbert Weissmann
    Research
    Nature Metabolism
    Volume: 2, P: 532-546

  • Cells of the pulmonary vasculature show a hyperproliferative phenotype in pulmonary arterial hypertension (PAH), thus contributing to the disease pathogenesis. Here the authors show that cyclin-dependent kinases are overactivated in PAH, and that their pharmacological inhibition attenuates the disease in two independent rodent models

    • Astrid Weiss
    • Moritz Christian Neubauer
    • Ralph Theo Schermuly
    ResearchOpen Access
    Nature Communications
    Volume: 10, P: 1-17

  • Pulmonary hypertension is characterized by a metabolic switch similar to the Warburg effect in cancer. Here Dabral et al. describe a RASSF1a-HIF-1α feedforward loop driving the Warburg effect both in a mouse model of hypoxia-induced pulmonary hypertension and a subset of human cancer cells.

    • Swati Dabral
    • Christian Muecke
    • Soni S. Pullamsetti
    ResearchOpen Access
    Nature Communications
    Volume: 10, P: 1-18

  • Phosphodiesterase 5 inhibitors augment endogenous nitric oxide signalling, thereby restoring vascular reactivity to diseased blood vessels. Ghofrani and colleagues review the evolution of the PDE5 inhibitor sildenafil from a potential anti-angina drug, to an on-demand oral treatment for erectile dysfunction, and its recent re-positioning as a pulmonary hypertension therapeutic.

    • Hossein A. Ghofrani
    • Ian H. Osterloh
    • Friedrich Grimminger
    Reviews
    Nature Reviews Drug Discovery
    Volume: 5, P: 689-702

  • The signalling cascade involved in lung ischaemia–reperfusion-induced oedema is poorly understood. Using knockout mice, Weissmannet al. propose a model in which reactive oxygen species production by endothelial NOX2 leads to phospholipase C-γ activation, DAG kinase inhibition and subsequent TRPC6 activation.

    • Norbert Weissmann
    • Akylbek Sydykov
    • Alexander Dietrich
    ResearchOpen Access
    Nature Communications
    Volume: 3, P: 1-10

  • In the past decade or so, our understanding of pulmonary arterial hypertension has undergone a paradigm shift. In this article, Dr Schermuly and colleagues discuss the known molecular mechanisms of the pathogenesis of this disease, and highlight the molecular technologies that are currently being used to further our understanding of these disease processes.

    • Ralph T. Schermuly
    • Hossein A. Ghofrani
    • Friedrich Grimminger
    Reviews
    Nature Reviews Cardiology
    Volume: 8, P: 443-455

  • Here, the authors discuss the potential of tyrosine kinase inhibitors — currently used for the treatment of cancer — as anti-proliferative agents in non-malignant disorders such as cardiac hypertrophy, pulmonary hypertension, lung fibrosis and rheumatoid disorders.

    • Friedrich Grimminger
    • Ralph T. Schermuly
    • Hossein A. Ghofrani
    Reviews
    Nature Reviews Drug Discovery
    Volume: 9, P: 956-970

  • In this Review, Ghofrani and colleagues discuss the mechanisms underlying the development of pulmonary arterial hypertension, provide an overview of approved therapies and describe the predominantly non-vasodilatory drugs that are currently being tested in clinical trials.

    • Hossein-Ardeschir Ghofrani
    • Mardi Gomberg-Maitland
    • Friedrich Grimminger
    Reviews
    Nature Reviews Cardiology
    Volume: 22, P: 105-120

  • Novoyatleva et al investigate the role of receptor tyrosine kinase Axl in Pulmonary arterial hypertension (PAH), finding that the small molecule inhibitor R428 reduces human pulmonary arterial smooth muscle cells proliferation and migration, but causes toxicity in human pulmonary arterial endothelial cells. They further show that Axl enhances endothelial BMPR2 signaling, altogether providing insights into mechanisms of PAH.

    • Tatyana Novoyatleva
    • Nabham Rai
    • Ralph T. Schermuly
    ResearchOpen Access
    Communications Biology
    Volume: 4, P: 1-16